Background: Daclatasvir is an inhibitor of HCV non-structural 5A protein and is a P-glycoprotein substrate. Pharmacogenetics has had a great impact on previous anti-HCV therapies, particularly considering the association of IL-28B polymorphisms with dual therapy outcome.
Introduction
New direct-acting antiviral drugs (DAAs) for the treatment of chronic hepatitis C (CHC) have enhanced the probability of achieving a sustained virological response (SVR) to nearly 100%. 1 Daclatasvir is an inhibitor of the non-structural HCVNS5A protein and its clinical effectiveness has also been demonstrated in patients who previously failed on treatment with first-generation PIs. 2 Monitoring the plasma concentration of daclatasvir is important to avoid the selection of resistant HCV variants. The daclatasvir active tissue concentration is substantially lower than the plasma concentration, highlighting a possible reason for the underestimation of the risk of developing resistance. 3 Daclatasvir is a P-glycoprotein (P-gp, encoded by the ABCB1 gene) substrate, as are boceprevir and telaprevir. SNPs in ABCB1 genes are able to affect the concentrations of these drugs; furthermore, ABCB11 (encoding the biliary salt export pump, BSEP, which is also known as the 'P-gp sister', as these two transporters show high homology) gene SNPs influence exposures to these drugs. 4, 5 Pharmacogenetics has had a great impact in the context of previous anti-HCV treatments: IL28B, SLC28A2 and vitamin D-related gene SNPs have been shown to affect therapy outcome and toxicity. [5] [6] [7] [8] [9] [10] [11] [12] To date, few data are available in the literature concerning pharmacogenetics and DAAs. 13, 14 For this reason, we investigated whether polymorphisms in genes encoding transporters and nuclear factors could affect daclatasvir plasma concentrations at 2 weeks and 1 month of treatment.
Patients and methods

Patients
Eighty-one CHC-monoinfected adult patients treated with daclatasvir and sofosbuvir, with or without ribavirin, were enrolled at the Amedeo di Savoia 
Ethics
The study was conducted in compliance with the Declaration of Helsinki and local review board regulations; all patients gave written informed consent, according to the local ethics committee standards ('Kinetic-C protocol', approved by the Ethics Committee of A.O.U. S. Luigi Gonzaga, Orbassano, Turin, number 186/14-26/05/2015).
Samples
Genomic DNA was isolated from blood samples (MagnaPure Compact, Roche, Monza, Italy) and genotypes were assessed through a real-time PCR allelic discrimination system (LightCycler 96, Roche, Monza, Italy). The SNPs investigated were ABCB13435 C . T (rs1045642), 1236
Pharmacokinetic evaluation was performed at the end of the dosing interval (C trough ), exactly before the next dose was taken. Daclatasvir quantification was performed through a UHPLC-MS/MS method, whereas ribavirin was quantified by a validated HPLC-UV method. 15 
Statistics
All variables were tested for normality through the Shapiro-Wilk test. Nonnormal variables were described as median (IQR); categorical variables were described as numbers and percentages. All polymorphisms were tested for Hardy-Weinberg equilibrium by the v 2 test. Kruskal-Wallis/ Mann-Whitney tests were used to test differences in continuous variables between genetic groups (a P value ,0.05 was considered significant).
The predictive power of the considered variables was evaluated through univariate (significance level P , 0.2) and multivariate (significance level P , 0.05) linear regression analysis.
All tests were performed with IBM SPSS Statistics 24.0 for Windows (Chicago, IL, USA).
Results and discussion
From a cohort of 81 enrolled subjects, pharmacokinetic data were available for 52 patients. 1-124.3) . The number of patients treated with ribavirin was 15 (28.8%) and median (IQR) drug concentrations were 1248 (701.5-1676.5) and 1414 ng/mL (822.8-2126.8) at 2 weeks and at 1 month, respectively, for ribavirin and 181 (126.5-249) and 212 ng/mL (120.5-307.5) for daclatasvir. SVR was achieved in all the patients.
No differences in daclatasvir concentrations were detected at 2 weeks (P " 0.250) and 1 month (P " 0.269). Concerning ribavirin use, median (IQR) daclatasvir concentrations were 169 (98.5-286) and 146 ng/mL (IQR 92-209) at 2 weeks and 189 (104-338) and 195 ng/mL (85-232) at 1 month for patients not taking and taking ribavirin, respectively.
HNF4a 975 C.G polymorphism influenced daclatasvir plasma concentrations (Figure 1 ) at 2 weeks (P " 0.009) and 1 month of therapy (P " 0.006): at 2 weeks CC genotype patients had a median concentration of 170 ng/mL (129.5-336), whereas this value for CG/GG patients was 92 ng/mL (61-181); at 1 month, CC genotype had 212 ng/mL (117.5-371) and CG/GG had 90 ng/mL (71-200).
In the linear regression analysis, we analysed all the different available variables and report only the significant ones (Table 1) . In the multivariate analysis, age, baseline BMI and haematocrit were found to be predictors of daclatasvir concentrations at 2 weeks, whereas at 1 month ABCB111131 CC and HNF4a CG/GG genotypes were predictive of daclatasvir concentrations.
The role of pharmacogenetics in affecting daclatasvir plasma concentrations was evaluated for the first time (to our knowledge). Daclatasvir is a P-gp substrate; in this study, we found a trend in ABCB11 and HNF4a SNPs and daclatasvir concentrations JAC plasma concentrations concerning ABCB1 gene SNPs, but no statistical difference was found (probably due to the small number of patients). Further studies in a larger cohort might show a statistically significant difference.
HNF4a is a transcription factor that modulates the expression of hepatic genes, including ABCB1, which encodes P-gp. A study reported that a small interfering RNA reduced HNF4a mRNA levels and also the mRNA levels of other genes, including ABCB1 and ABCB11, suggesting that the expression of these genes would be directly enhanced by HNF4a. 16 For these reasons, we decided to analyse this transcription factor gene SNP to understand whether it could affect ABCB1 and ABCB11 gene transcription and, consequently, daclatasvir plasma concentrations. Here, we found that CC genotype patients had increased daclatasvir concentrations compared with other genotype patients. This evidence agrees with our previous study: CC patients showed higher efavirenz plasma levels compared with other genotypes. 17 Furthermore, we have also suggested an influence of this polymorphism on raltegravir CSF and CSF/plasma ratio concentrations. 18 The HNF4a 975 C . G SNP is located upstream of the HNF4a promoter and it has no known function. 17 Bile salts are secreted from hepatocytes into the bile by BSEP; altered BSEP activity leads to the accumulation of bile salts within hepatocytes. ABCB111131 T . C is a non-synonymous variant associated with reduced BSEP transporter levels; serum bile acid concentrations were higher in CC compared with TT patients. 4 Our previous data showed that TT patients had lower telaprevir concentrations compared with TC and CC ones, confirming the potentially reduced transport activity in C carriers. Concerning daclatasvir, we found that CC patients had lower concentrations compared with other genotypes and this is in contrast to the situation observed with telaprevir. 4 As mentioned, daclatasvir is a P-gp substrate and no data are present in the literature concerning BSEP; furthermore, the number of patients in our study is relatively small and only one cohort was analysed. For these reasons, further studies in larger and different cohorts are required to confirm and validate our preliminary results from the Kineti-C study, since data on the relationship between pharmacogenetic and pharmacokinetic profiles of daclatasvir are lacking in the literature. Cusato et al.
